Bifidobacteria support optimal infant vaccine responsesOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
The study tested whether early-life antibiotic exposure impairs infant vaccine responses and how the gut microbiome is involved. It used a systems vaccinology approach combining antibody testing, blood transcriptomics, flow cytometry and faecal metagenomics. Infants were followed prospectively from birth to 15 months. Preclinical experiments in germ-free and antibiotic-treated mice tested whether Bifidobacterium species or a clinical probiotic could restore responses to the pneumococcal conjugate vaccine.
Who was studied?
The study prospectively enrolled 191 healthy, vaginally born, full-term infants in Adelaide, Australia. Eighty had no antibiotic exposure and 111 were exposed, subdivided into 32 direct neonatal, 49 intrapartum and 30 postnatal exposure infants. Infants received routine vaccines including the 13-valent pneumococcal conjugate vaccine and the 6-in-1 Infanrix Hexa vaccine. Germ-free, specific-pathogen-free and gene-knockout mice were used for the mechanistic experiments.
What were the most important findings?
Direct neonatal antibiotics, but not intrapartum antibiotics, were linked to lower IgG titres at 7 months against several pneumococcal polysaccharides (PPS1, 6B, 9V, 18C, 19F, 23F), Hib polyribosylribitol phosphate and diphtheria toxoid. Neonatal-antibiotic infants had an inflammatory blood transcriptome before vaccination and reduced Bifidobacterium at week 6, which correlated with lower titres six months later. Germ-free mice had impaired pneumococcal vaccine responses that were restored by a Bifidobacterium consortium or the Infloran probiotic used in neonatal units.
What are the greatest implications of this study?
The findings suggest that Bifidobacterium species support optimal infant vaccine responses and that neonatal antibiotics can blunt immunity by depleting them. Conjugate polysaccharide vaccines like PCV13 appear especially microbiome-dependent. The mouse data indicate that a safe, already-used probiotic could mitigate this effect, pointing toward precision vaccination strategies. The cohort was modest and observational for the human arm, so randomized trials are needed. The authors also broaden the rationale for antibiotic stewardship in early life.